Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole Magnesium vs Esomeprazole in Erosive GERD
NCT01132638Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Panzobax in erosive gastroesophageal reflux disease (2 arms), sponsored by Takeda. Primary endpoint: Proportion of patients in complete remission at 4 weeks. Started Aug 2011; status: completed.
02
Drugs
Panzobax
03
Conditions
erosive gastroesophageal reflux disease
Beyond the preview
Go deeper on NCT01132638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132638.